Sign In
Buy ASLN
$0.600
+0 (+0%)
At Close: Oct 17, 2024
Critical Contrast: ASLAN Pharmaceuticals (NASDAQ:ASLN) vs. Argos Therapeutics (OTCMKTS:ARGSQ)
02:07am, Monday, 23'rd Mar 2026
Profitability This table compares Argos Therapeutics and ASLAN Pharmaceuticals' net margins, return on equity and return on assets. Net Margins Return on Equity Return on Assets Argos Therapeutics N/A
Analyzing ASLAN Pharmaceuticals (NASDAQ:ASLN) & CannTrust (OTCMKTS:CNTTF)
01:31am, Saturday, 21'st Mar 2026
Valuation and Earnings This table compares CannTrust and ASLAN Pharmaceuticals"s gross revenue, earnings per share (EPS) and valuation. Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Pr
SAN MATEO, Calif. and SINGAPORE, July 17, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (“ASLAN” or the “Company”), a clinical-stage, immunology-focused biopharmaceutical company developing i
ASLAN Pharmaceuticals Announces Receipt of Nasdaq Delisting Determination; Has Determined Not to Appeal
07:30am, Monday, 15'th Jul 2024
SAN MATEO, Calif. and SINGAPORE, July 15, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (“ASLAN” or the “Company”, Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical compan
All You Need to Know About ASLAN Pharmaceuticals (ASLN) Rating Upgrade to Buy
01:01pm, Tuesday, 04'th Jun 2024
ASLAN Pharmaceuticals (ASLN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Here's Why ASLAN Pharmaceuticals (ASLN) Could be Great Choice for a Bottom Fisher
10:56am, Tuesday, 04'th Jun 2024
ASLAN Pharmaceuticals (ASLN) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions co
SAN MATEO, Calif. and SINGAPORE, May 21, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments
ASLAN Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
07:00am, Thursday, 09'th May 2024
SAN MATEO, Calif. and SINGAPORE, May 09, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments
SAN MATEO, Calif. and SINGAPORE, May 07, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments
SAN MATEO, Calif. and SINGAPORE, May 02, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments
SAN MATEO, Calif. and SINGAPORE, April 30, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatment
Interim readout of 22 patients shows unprecedented efficacy data compared to prior atopic dermatitis (AD) studies with biologics: 60.0% of dupilumab -experienced AD patients treated with 400mg eblasak
ASLAN Pharmaceuticals Announces Receipt of Nasdaq Notice
05:10pm, Friday, 19'th Apr 2024
SAN MATEO, Calif. and SINGAPORE, April 19, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatment
ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
08:00am, Friday, 12'th Apr 2024
SAN MATEO, Calif. and SINGAPORE, April 12, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatment
Are Medical Stocks Lagging ASLAN Pharmaceuticals (ASLN) This Year?
10:45am, Tuesday, 09'th Apr 2024
Here is how ASLAN Pharmaceuticals Ltd. (ASLN) and Assembly Biosciences (ASMB) have performed compared to their sector so far this year.
